Names | ||||
---|---|---|---|---|
Preferred IUPAC Name : (8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one |
Other Names : Dexamethasone corticosteroid |
|||
Identifiers & Properties | ||||
CAS Number | 2392-39-4 | Appearance:
Odour: |
A White or almost white powder Odourless Powder |
|
Chemical formula | C22 H28 FNa2O 8P | RS Single Impurity: RS Total Impurity: |
NMT-0.5 % NMT-1.0 % |
|
Molar mass | 392.467 g·mol−1 | HPLC : | NLT 99.0 % | |
Specific Optical Rotation: | +72.0° to +80.0° | Assay By HPLC: | 96.0% to 104.0% | |
Pharmacology | ||||
Routes of administration | By mouth, sublingual, injection, Drops, spray. |
Names | ||||
---|---|---|---|---|
Preferred IUPAC Name : (8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one |
Other Names : Hexadrol Phosphate |
|||
Identifiers & Properties | ||||
CAS Number | 50-02-2 | Appearance:
Odour: |
A White or almost white powder Odourless Powder |
|
Chemical formula | C22 H29 FO 5 | RS Total Impurity: | NMT - 1.0 % | |
Molar mass | 516.4 g·mol−1 | HPLC : | NLT 99.0 % | |
Specific Optical Rotation: | +75.0° to +83.0° | Assay By HPLC: | 97.0% to 102.0% | |
Pharmacology | ||||
Routes of administration | By mouth, sublingual, injection, Drops, spray. |
Names | ||||
---|---|---|---|---|
Preferred IUPAC Name : (8S,9R,10S,11S,13S,14S,16S,17R)-9-Fluoro- 11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl- 6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro- 3H-cyclopenta[a]phenanthren-3-one |
Other Names : Betamethasonum |
|||
Identifiers & Properties | ||||
CAS Number | 378-44-9 | Appearance:
Odour: |
A White or almost white powder Odourless Powder |
|
Chemical formula | C22 H29 FO 5 | RS Total Impurity: | NMT - 2.0 % | |
Molar mass | 392.46 g·mol−1 | HPLC : | NLT 98.0 % | |
Specific Optical Rotation: | +118.0° to +126.0° | Assay | 96.0% to 104.0% | |
Pharmacology | ||||
Routes of administration | By mouth, topical, intramuscular |
Names | ||||
---|---|---|---|---|
Preferred IUPAC Name : Disodium; [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate |
Other Names : Betamethasone 21-phosphate disodium |
|||
Identifiers & Properties | ||||
CAS Number | 151-73-5 | Appearance:
Odour: |
A White or almost white powder Odourless Powder |
|
Chemical formula | C22 H28 FNa2 O8 P | RS Total Impurity: | NMT - 3.0 % | |
Molar mass | 516.4 g/mol | HPLC : | NLT 97.0 % | |
Specific Optical Rotation: | +98.0° to + 104.0° | Assay By HPLC: | 96.0% to 103.0% | |
Pharmacology | ||||
Routes of administration | By mouth, sublingual, injection, Drops, spray. |
Names | ||||
---|---|---|---|---|
Preferred IUPAC Name : [17-(2'-Chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate |
Other Names : Clobetasol 17-propanoate |
|||
Identifiers & Properties | ||||
CAS Number | 25122-46-7 | Appearance:
Odour: |
A White or almost white powder, crystalline powder Odourless Powder |
|
Chemical formula | C25 H32 CIFO5 | RS Total Impurity: | NMT - 2.0 % | |
Molar mass | 466.97 g·mol−1 | HPLC : | NLT 98.0 % | |
Specific Optical Rotation: | +112.0° to + 118.0° | Assay By HPLC: | 97.0% to 102.0% | |
Pharmacology | ||||
Routes of administration | By mouth, sublingual, injection, Drops, spray. |
Names | ||||
---|---|---|---|---|
Preferred IUPAC Name : (16β)-21-Chloro-9-fluoro-16-methyl-3,11,20-trioxopregna-1,4-dien-17-yl butyrate |
Other Names : Clobetasone 17-butyrate |
|||
Identifiers & Properties | ||||
CAS Number | 25122-57-0 | Appearance:
Odour: |
A White or almost white powder Odourless Powder |
|
Chemical formula | C26 H32 CIFO5 | RS Single Impurity: RS Total Impurity: |
NMT - 0.1 % NMT - 0.5% |
|
Molar mass | 478.99 g·mol−1 | HPLC : | NLT 99.5 % | |
Specific Optical Rotation: | +131.0° to + 138.0° | Assay By UV: | 97.0% to 102.0% | |
Pharmacology | ||||
Routes of administration | By mouth, sublingual, injection, Drops, spray. |
Names | ||||
---|---|---|---|---|
Preferred IUPAC Name : [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
Other Names : mometasone 17-furoate, Mometasone furoate anhydrous |
|||
Identifiers & Properties | ||||
CAS Number | 83919-23-7 | Appearance:
Odour: |
A White or almost white powder Odourless Powder |
|
Chemical formula | C27 H30 CI2 O6 | RS Total Impurity: | NMT - 0.3 % | |
Molar mass | 521.43 g·mol−1 | HPLC : | NLT 99.4 % | |
Specific Optical Rotation: | +50.0° to + 55.0 | Assay By HPLC: | 97.0% to 102.0% | |
Pharmacology | ||||
Routes of administration | By mouth, sublingual, injection, Drops, spray. |
Names | ||||
---|---|---|---|---|
Preferred IUPAC Name : (11β,16β)-21-(Acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d] oxazole-3,20-dione |
Other Names : Deflazacort |
|||
Identifiers & Properties | ||||
CAS Number | 14484-47-0 | Appearance:
Odour: |
White to creamy white crystalline powder | |
Chemical formula | C25 H31 NO6 | RS Total Impurity: | NMT - 2.0 % | |
Molar mass | 441.52 g·mol−1 | HPLC : | NLT 98.0 % | |
Specific Optical Rotation: | +57.0° to + 65.0° | Assay By HPLC: | 97.0% to 102.0% | |
Pharmacology | ||||
Routes of administration | By mouth |
Names | ||||
---|---|---|---|---|
Preferred IUPAC Name : 4-[2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid |
Other Names : Methylprednisolone 21-succinate sodium salt |
|||
Identifiers & Properties | ||||
CAS Number | 2375-03-3 | Appearance: Odour: |
White or nearly white, odourless, hygroscopic, amorphous solid Powder | |
Chemical formula | C26 H33 NaO8 | Specific Optical Rotation : | +96.0° to + 104.0° | |
Molar mass | 496.5 g·mol−1 | Assay : | 97.0% to 102.0% | |
Pharmacology | ||||
Routes of administration | Intravenous, intramuscular injection. |